



(11) **EP 3 540 100 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(51) International Patent Classification (IPC):
C40B 50/00 ^(2006.01) **C40B 40/10** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C12N 15/1044; C40B 40/08; C40B 50/06

(48) Corrigendum issued on:
02.11.2022 Bulletin 2022/44

(45) Date of publication and mention
of the grant of the patent:
17.08.2022 Bulletin 2022/33

(21) Application number: **18210289.7**

(22) Date of filing: **27.09.2012**

(54) **FIBRONECTIN TYPE III REPEAT BASED PROTEIN SCAFFOLDS WITH ALTERNATIVE BINDING SURFACES**

AUF FIBRONEKTIN-TYP-III-REPEAT BASIERENDE PROTEINGERÜSTE MIT ALTERNATIVEN
BINDUNGSOBERFLÄCHEN

ÉCHAFAUDAGE DE PROTÉINE À BASE DE RÉPÉTITION DE FIBRONECTINE DE TYPE III AVEC
DES SURFACES DE LIAISON ALTERNATIVES

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

(30) Priority: **27.09.2011 US 201161539670 P**

(43) Date of publication of application:
18.09.2019 Bulletin 2019/38

(60) Divisional application:
22190632.4

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
12834641.8 / 2 761 066

(73) Proprietor: **Janssen Biotech, Inc.**
Horsham, PA 19044 (US)

(72) Inventors:
• **Diem, Michael**
Spring House, PA 19044 (US)
• **Jacobs, Steven**
Spring House, PA 19477 (US)

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

(56) References cited:
WO-A2-2010/051274 WO-A2-2011/137319
US-A1- 2005 038 229

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 540 100 B8